- Home
- CALC vs CMBM Comparison
CALC vs CMBM Comparison
Compare CALC & CMBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALC
- CMBM
- Stock Information
- Founded
- CALC 2011
- CMBM 2011
- Country
- CALC United States
- CMBM United States
- Employees
- CALC N/A
- CMBM N/A
- Industry
- CALC Biotechnology: Pharmaceutical Preparations
- CMBM Radio And Television Broadcasting And Communications Equipment
- Sector
- CALC Health Care
- CMBM Technology
- Exchange
- CALC Nasdaq
- CMBM Nasdaq
- Market Cap
- CALC 45.4M
- CMBM 17.7M
- IPO Year
- CALC N/A
- CMBM 2019
- Fundamental
- Price
- CALC $2.97
- CMBM $2.95
- Analyst Decision
- CALC Strong Buy
- CMBM Buy
- Analyst Count
- CALC 2
- CMBM 1
- Target Price
- CALC $14.50
- CMBM $3.00
- AVG Volume (30 Days)
- CALC 48.2K
- CMBM 24.1M
- Earning Date
- CALC 11-07-2025
- CMBM 11-11-2025
- Dividend Yield
- CALC N/A
- CMBM N/A
- EPS Growth
- CALC N/A
- CMBM N/A
- EPS
- CALC N/A
- CMBM N/A
- Revenue
- CALC N/A
- CMBM $172,215,000.00
- Revenue This Year
- CALC N/A
- CMBM N/A
- Revenue Next Year
- CALC N/A
- CMBM $17.73
- P/E Ratio
- CALC N/A
- CMBM N/A
- Revenue Growth
- CALC N/A
- CMBM N/A
- 52 Week Low
- CALC $1.42
- CMBM $0.23
- 52 Week High
- CALC $5.65
- CMBM $4.18
- Technical
- Relative Strength Index (RSI)
- CALC 42.55
- CMBM 88.69
- Support Level
- CALC $3.04
- CMBM $0.60
- Resistance Level
- CALC $3.14
- CMBM $0.71
- Average True Range (ATR)
- CALC 0.18
- CMBM 0.26
- MACD
- CALC -0.03
- CMBM 0.13
- Stochastic Oscillator
- CALC 1.45
- CMBM 65.64
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
About CMBM Cambium Networks Corporation
Cambium Networks Corp provides wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises, and government agencies. The company geographically operates in North America; Europe, Middle East and Africa; Caribbean and Latin America; and Asia Pacific. It derives maximum revenue from North America.